Archives: Agenda

Adaptive Oncology Trials: Improving Access and the Patient Perspective

This session explores how adaptive trial designs are changing oncology research, enabling greater flexibility in trial arms and broader use of therapies across indications. We will discuss what this means for patient access and why embedding patient perspectives early is critical to successful study design and delivery.

ROUNDTABLE DISCUSSIONS

During the roundtable discussion session, the conference hall will be divided into zones. Delegates can choose which zone they would like to join. Each zone will be led by a table lead/host and will focus on a different challenge within the industry. After 30 minutes, delegates will have the opportunity to swap and choose a different table, and each roundtable will run twice.

 

ROUNDTABLE 1: Taking the Wheel: Gaining Control of Your eTMF During Active Trials

Jane Silverwood, Clinical Documental Management Specialist, Owkin
ROUNDTABLE 2: Beyond the CRO: What Clinical-Stage Biotech Actually Needs from an Execution Partner

Kamil Sitarz, PhD, EMBA, Chief Operating Officer, Ryvu Therapeutics
ROUNDTABLE 3: Developing medicines from analysis of real-world data

Myles Dakin, Chairman & Founder, Hypo-Stream
ROUNDTABLE 4: AI in Clinical Trials: Who Owns the Risk When Development is Outsourced?

Surbhi Gupta, Advisor to National AI team, NHS England
ROUNDTABLE 5: Can FAST-EU realistically accelerate multinational trial start-up, or will operational reality slow it down?

Victoria Toms, Executive Director, International Accrediting Organisation for Clinical Research (IAOCR)

 

 

 

 

 

 

Optimising Clinical Trial Feasibility: From Site Selection to Study Design

  • Assessing site capabilities, patient populations, and operational resources to ensure realistic trial execution.
  • Using data-driven approaches and analytics to predict enrollment timelines and potential bottlenecks.
  • Identifying and mitigating risks early to improve study efficiency and reduce delays.
  • Incorporating patient insights and stakeholder feedback to design feasible, patient-friendly protocols.

From the Health Dividend of Peace to the Economic Dividend of Health: A Tale of Politics, Pragmatism and Progress Strength in Collaboration: How a Unified cancer approach Is driving growth and cross-border innovation

  • The Good Friday Agreement: How politics helped deliver the health dividend of peace on the island of Ireland
  • The All-Island Cancer Research Institute (AICRI) a united approach to cancer research and innovation
  • How a collaborative cancer research and innovation agenda is empowering the island of Ireland to punch above its weight
  • How a unified national collaborative clinical trials ecosystem, underpinned by the formation of the National Clinical Trials Oversight Group, is raising the bar and delivering innovative treatments for Irish patients
  • Empowering the Economic Dividend of Health: Providing the innovation and research excellence milieu for industry and academic clinical trials and Real-World Evidence studies to flourish North, South, East and West: maximising the opportunities for cross-border success